---
schema_version: "secwatch.filing_event.v1"
accession: "0001842952-24-000022"
form_type: "8-K"
ticker: "CNTX"
cik: "0001842952"
company_name: "Context Therapeutics Inc."
filed_at: "2024-04-01T23:59:59+00:00"
generated_at: "2026-06-04T04:55:31.726510+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Context Therapeutics submits IND for CTIM-76 Phase 1 trial in CLDN6-positive cancers

## Summary
- IND filed March 28, 2024 with FDA for CTIM-76, a CLDN6 x CD3 bispecific antibody.
- Phase 1 dose escalation/expansion trial planned in CLDN6-positive gynecologic and testicular cancers.
- CEO Martin Lehr calls IND submission a significant milestone for the company.
- Company set aggressive 2021 timeline and prioritized CTIM-76 as potentially best-in-class therapy.

## SEC filing metadata
- accession: 0001842952-24-000022
- form_type: 8-K
- ticker: CNTX
- cik: 0001842952
- company_name: Context Therapeutics Inc.
- filed_at: 2024-04-01T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842952/000184295224000022/0001842952-24-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842952/000184295224000022/cntx-20240401.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001842952-24-000022
- JSON: https://secwatch.observer/filing/0001842952-24-000022.json
- Plain text: https://secwatch.observer/filing/0001842952-24-000022.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.